ESMO: Jemperli appears to show survival edge over Keytruda

Last year, a first-of-its-kind head-to-head clinical trial between two PD-1 inhibitors went in GSK’s favor. Now, the British pharma has some new patient survival data to celebrate. Compared with Merck’s market-leading Keytruda, GSK’s Jemperli demonstrated a 25% lower risk of death in patients with…#pd1 #gsk #merck #keytruda #nsclc #heshamabdullah #fiercepharma #jemperli #pdl1negative #pdl1
Source: Reuters: Health - Category: Consumer Health News Source Type: news